55 results about "Epithelial barrier" patented technology

The invention discloses an eye drop for treating eye dryness. The pH value of the eye drop is 5.0-7.0, the eye drop comprises effective components of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, and specifically the eye drop consists of the following components in percentage by weight: 0.05-0.1% of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, a proper amount of a pH value adjusting agent, 0.01-3% of an iso-osmotic agent, 0.003-0.5% of a bacteriostatic agent, 0.001-0.5% of a stabilizer, 0.01-0.5% of a tackifier, 2-5% of a solubilizer and the balance of water. Through partial treatment of the eye drop, epithelial barrier functions of dry eye mouse cornea can be protected, the number of goblet cells of cornea can be recovered, and relatively good anti-inflammatory and immunity inhibition effects can be achieved.

Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.

This present application relates to a drug delivery method. In particular, the present invention discloses a non-invasive drug delivery method using Listeria adhesion protein (LAP) an analogue, or a fragment thereof. Incorporation of those peptides or a fragment thereof, either by a physical mixture of a pharmaceutical formulation or as a covalent construction at a molecular level or nanoscale is within the scope of this disclosure.

A method for constructing a xerophthalmia model in vitro relates to a xerophthalmia model. A method for constructing a xerophthalmia model in vitro with easy operation, good repeatability, lower cost than animal model and a plurality of similar histopathological characteristics similar to xerophthalmia and application thereof in simulating, studying and preventing xerophthalmia are provided. The conjunctiva tissue containing conjunctival epithelium and conjunctival submucosa is cut and placed in culture media; the conjunctiva tissue is trimmed into a conjunctiva tissue block which is placed on a culture vessel inserter coated by type I collagen, with conjunctival epithelium being upward; the culture media are added into the culture vessel outside the inserter to cause the gas-liquid interface of the culture media to be at the junction of the conjunctival epithelium and conjunctival submucosa of the conjunctiva tissue block; and the conjunctiva tissue block is placed into a culture tank to be cultured. The xerophthalmia model in vitro can be used for such researches as xerophthalmia squamous epithelium metaplasia, ocular surface epithelial barrier breakdown, ocular surface epithelial mucoprotein change, and function of the participation and atopsis of inflammatory mediator in xerophthalmia diseases in the generation and development of xerophthalmia.